Patton Albertson Miller Group LLC Raises Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Patton Albertson Miller Group LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,446 shares of the medical research company’s stock after purchasing an additional 500 shares during the period. Patton Albertson Miller Group LLC’s holdings in Thermo Fisher Scientific were worth $7,515,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of TMO. AQR Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 18.1% during the 2nd quarter. AQR Capital Management LLC now owns 98,152 shares of the medical research company’s stock valued at $54,278,000 after purchasing an additional 15,009 shares in the last quarter. Daymark Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 24.5% in the second quarter. Daymark Wealth Partners LLC now owns 619 shares of the medical research company’s stock worth $342,000 after acquiring an additional 122 shares during the period. Sepio Capital LP boosted its stake in shares of Thermo Fisher Scientific by 7.6% during the 2nd quarter. Sepio Capital LP now owns 3,980 shares of the medical research company’s stock worth $2,201,000 after acquiring an additional 282 shares in the last quarter. Goodman Advisory Group LLC grew its position in shares of Thermo Fisher Scientific by 40.9% during the 2nd quarter. Goodman Advisory Group LLC now owns 465 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 135 shares during the period. Finally, Kathmere Capital Management LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth about $375,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.1 %

TMO stock opened at $575.21 on Friday. The firm has a market cap of $220.02 billion, a PE ratio of 36.06, a PEG ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm’s 50 day moving average price is $533.60 and its 200-day moving average price is $569.32.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.69 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,850 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $557.89, for a total value of $3,263,656.50. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,611,804.88. The trade was a 4.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 44,850 shares of company stock worth $24,666,097. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Bank of America cut their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Morgan Stanley decreased their price target on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Finally, Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.